| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ent-Ezetimibe targets the same cholesterol absorption pathway as its parent drug, Ezetimibe. However, as the enantiomer, it is significantly less active as a cholesterol absorption inhibitor. Its primary use is as a reference standard for chiral purity analysis of Ezetimibe.
|
|---|---|
| ln Vitro |
In vitro, ent-Ezetimibe is characterized as the enantiomer of Ezetimibe. It is significantly less active as a cholesterol absorption inhibitor compared to the parent drug. Its activity makes it a valuable tool for studying the stereospecificity of cholesterol absorption inhibition.
|
| ln Vivo |
In vivo, ent-Ezetimibe is not used as a therapeutic agent. It is the enantiomer of Ezetimibe and is used as a reference standard for analytical method development and quality control. Its in vivo effects are not characterized, as it is not intended for human use.
|
| Enzyme Assay |
In vitro assays for ent-Ezetimibe typically involve analytical method development using chiral HPLC or LC-MS. The compound is used as a reference standard to identify and quantify the enantiomeric impurity in Ezetimibe samples. Its retention time and mass spectrum are characterized for method validation.
|
| Cell Assay |
For in vitro cell-based assays, ent-Ezetimibe is not typically used, as it is an enantiomeric impurity and not a pharmacological agent. It could be used to study its potential effects on cholesterol absorption if necessary, but its primary role is as an analytical reference standard.
|
| Animal Protocol |
In vivo animal studies with ent-Ezetimibe are not typically performed, as it is an enantiomeric impurity and not a therapeutic candidate. Its use is confined to analytical and quality control applications. The compound is not intended for in vivo pharmacological evaluation.
|
| ADME/Pharmacokinetics |
ent-Ezetimibe (CAS: 1376614-99-1) has a molecular weight of 409.40 g/mol and a molecular formula of C24H21F2NO3. Appearance: solid powder. Purity: ≥95%. Storage: -20°C. The compound is the enantiomer of Ezetimibe.
|
| Toxicity/Toxicokinetics |
ent-Ezetimibe is a research compound and is not approved for human therapeutic use. As an enantiomeric impurity standard, it is used in very small quantities and does not pose significant toxicity risks under normal handling. Standard laboratory safety precautions should be followed when handling the compound.
|
| Additional Infomation |
See also: Ezetimibe (note moved to).
ent-Ezetimibe is the enantiomer of Ezetimibe, a selective inhibitor of cholesterol absorption. It is used as a reference standard for analytical method development and quality control. It is not FDA-approved as a drug and is intended for research and analytical use only. |
| Molecular Formula |
C₂₄H₂₁F₂NO₃
|
|---|---|
| Molecular Weight |
409.43
|
| Exact Mass |
409.149
|
| CAS # |
1376614-99-1
|
| PubChem CID |
69281225
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.953
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
567
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O
|
| InChi Key |
OLNTVTPDXPETLC-ZRBLBEILSA-N
|
| InChi Code |
InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m0/s1
|
| Chemical Name |
(3S,4R)-1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
|
| Synonyms |
entEzetimibe ent Ezetimibe
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4424 mL | 12.2121 mL | 24.4242 mL | |
| 5 mM | 0.4885 mL | 2.4424 mL | 4.8848 mL | |
| 10 mM | 0.2442 mL | 1.2212 mL | 2.4424 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
